Scientists test Two-Pronged attack on tough cancers
NCT ID NCT02856425
Summary
This early-stage trial tested a new combination of two existing drugs—an immunotherapy (pembrolizumab) and a drug that blocks blood vessel growth (nintedanib)—in patients with various advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of nintedanib when used with pembrolizumab. Researchers hoped the two drugs would work better together to help control cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ANY ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Hôpital Bichat
Paris, 75018, France
-
IUCT--O
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33000, France
Conditions
Explore the condition pages connected to this study.